Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier

Magnetic Resonance Imaging

Volumn 14, Issue 6, 1996, Pages 619-623

  Takahashi, Masaya ^a   Tsutsui, Hirokazu ^a   Murayama, Chie ^a   Miyazawa, Tomoaki ^a   Fritz Zieroth, Bernhard ^a  

^a Research Department   (Japan)

Author keywords

Animals; Blood brain barrier; Gadolinium complexes; MRI contrast agents; Neurotoxicity

Indexed keywords

GADOLINIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SCINTISCANNING; CONCENTRATION RESPONSE; IMAGE ENHANCEMENT; MALE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

ANIMALIA;

EID: 0029859702     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0730-725X(96)00118-X     Document Type: Article

References (24)

1. 1. Weinmann, H.-J.; Brash, R.C.; Press, W-R.; Wesbey, G.E. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. AJR 142:619-624; 1984.
2. 2. Goldstein, H.A.; Kashianian, F.K.; Blumetti, R.F.; Holyoak, W.L. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 174:17-23; 1990.
3. 3. Hywang, S.H.; Wolff, A.; Pruss, E.; Hilbertz, T.; Eiermann, W.; Permanetter, W. MR imaging of the breast with Gd-DTPA: Use and Limitations, cerebral ischemia: MR enhancement using Gd-DTPA. Radiology 158:701-705; 1986.
4. 4. Runge, V.M.; Clantan, L.A.; Prince, A.C.; Wehr, C.J.; Herzer, W.A.; Partain, C.L.; James, A.V., Jr. The use of Gd-DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn. Reson. Imaging 3:43-55; 1995.
5. 5. McNamara, M.T.; Brant-Zawadzki, M.; Berry, I.; Pereria, B.; Weinstein, P.; Perugin, N.; Moore, S.; Kucharczyk, W.; Brash, R.C. Acute experimental cerebral ischemia: MR enhancement using Gd-DTPA. Radiology 158:701-705; 1986.
6. 6. Takahashi, M.; Fritz-Zieroth, B.; Yamaguchi, M.; Ogawa, H.; Tanaka, T.; Sasagawa, S.; Chikugo, T.; Ohta, Y.; Okamoto, K. MR imaging of cerebral lesions accompanying stroke in stroke-prone spontaneously hypertensive rats. Folia Pharmacol. Jpn. 100:21-28; 1992.
7. 7. Takahashi, M.; Fritz-Zieroth, B.; Ohta, Y.; Chikugo, T. Therapeutic effects of imidapril on cerebral lesions observed by magnetic resonance imaging in malignant stroke-prone spontaneously hypertensive rats. J. Hypertens. 12:761-768; 1994.
8. 8. Olukotun, A.Y.; Parker, J.R.; Meeks, M.J.; Lucas, M.A.; Fowler, D.R.; Lucas, T.R. Safety of gadoteridol injection: U.S. clinical trial experience. J. Magn. Reson. Imag. 5:17-25; 1995.
9. 9. Allen, C.C. Magnetic resonance imaging contrast agents; Design and physicochemical properties of gadodiamide. Invest. Radiol. 28:S21-S27; 1993.
10. 10. Harpur, E.S.; Worah, D.; Hals, P.-A.; Holtz, E.; Furuhama, K.; Nomura, H. Preclinical safety assessment and pharmacokinetics of gadodiamid injection, a new magnetic resonance imaging contrast agent. Invest. Radiol. 28:S28-S43; 1993.
11. 11. McLachlan, S.J.; Eaton, S.; De Simone, D.N. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol. 27:S12-S15; 1992.
12. 12. Weinmann, H.-J.; Press, W.-R.; Gries, H. Tolerance of extracellular contrast agents for magnetic resonance imaging. Invest. Radiol. 25:S49-S50; 1990.
13. 13. Rapoport, S.I.; Fredericks, W.R.; Ohno, K.; Pettigrew, K.D. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. J. Physiol. 238:R421-R431; 1980.
14. 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 48:449-566; 1988.
15. 15. Runge, V.M.; Price, A.C.; Wehr, C.J.; Atkinson, J.B.; Tweedle, M.F. Contrast enhanced MRI: Evaluation of a canine model of osmotic blood-brain barrier disruption. Invest. Radio. 20:830-844; 1985.
16. 16. Roman-Goldstein, S.M.; Barnet, P.A.; McCormik, C.I.; Szumowski, J.; Shannon, E.M.; Ramsey, F.L.; et al. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: Toxicity and MR findings. J. Comput. Assist. Tomogr. 18:731-736; 1994.
17. 17. Sovak, M. Introduction: State of the art and desigh principle of contrast media. In: M. Sovak (Ed). Ward Book of Experimental Pharmacology, 1st ed. Berlin, Heidelberg: Springer-Verlag; 1984: pp. 1-22.
18. 18. Tweedle, M.F. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest. Radiol. 27:S2-S6; 1992.
19. 19. Wedking, P.; Kumar, K.; Tweedle, M.F. Dissociation of gadolinium chelates in mice: Relationship to chemical characteristics. Magn. Reson. Imaging 10:641-648; 1992.
20. 20. Higgins, C.B.; Gerber, K.H.; Mattrey, R.F.; Slutsky, R.A. Evaluation of the hemodynamic effects of intravenous administration of ionic and nonionic contrast materials. Radiology 142:681-686; 1982.
21. 21. Press, W.-R.; Mützel, W.; Schbel, C. Tolerance to iotrolan after subarachnoid injection in animals. In: V. Taenzer; S. Wende (eds). Recent Developments in Non-Ionic Contrast Media. New York: Thieme; 1989: pp. 126-133.
22. 22. Miyazawa, T.; Sho, C.; Nakagawa, H.; Oshino, N. Effect of water-soluble contrast medium on the lung in rats: Comparison of iotrolan, iopamidol and diatrizoate. Invest. Radiol. 25:999-1003; 1990.
23. 23. Nguyen, C.; An, H.; Ho, K.C.; Haughton, V.M.; Hasegawa, T. Contrast enhancement for detecting recurrent herniated intervertebral discs: Utility of increased dose. AJNR 15:419-423; 1994.
24. 24. Ibrahim, M.A.; Haughton, V.M.; Hyde, J.S. Enhancement of Intervertebral discs with gadolinium complexes: Comparison of an ionic and a nonionic medium in an animal model. AJNR 15:1907-1910; 1994.